- Alphyn Biologics Completes First Cohort of Phase 2a Clinical Trial of a Therapeutic Topical Treatment for Mild to Moderate Atopic Dermatitis
ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing world-class multi-target therapies, announced today that it has completed the first cohort of its Phase 2a clinical trial of AB- 101a, a topical therapeutic candidate for patients with mild to moderate atopic dermatitis (AD) in adults and children from 2 years of age. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in about eight weeks.
The randomized, double-blind, vehicle-controlled trial is evaluating the AB-101a treatment protocol at multiple sites using standard scales to assess AD. Enrollment is ongoing in a second cohort of the trial, which is solely investigating treatment in AD patients who also have bacterial infections, including Staphylococcus aureus, or Staph, and MRSA, the antibiotic-resistant Staph. Alphyn anticipates that AB-101a will be effective against both uninfected AD and infected AD and hopes that it will offer patients and physicians a comprehensive, safe and convenient treatment option.
AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform has multiple bioactive compounds and thus multiple mechanisms of action to potentially address multiple problems of any target disease. Alphyn began its Phase 2 clinical trial program due to the strong safety profile of its AB-101 platform.
ABOUT ALPHYN BIOLOGICS
Alphyn Biologics is a clinical-stage dermatology company developing world-class multi-target therapies for prevalent and serious skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is being developed as a topical treatment for atopic dermatitis (AD), the most common form of eczema. AB-101a has demonstrated a strong safety profile and is in development to uniquely target the immune system and bacterial components of AD, making it ideal for treating infected and uninfected AD. Alphyn's AB-101 platform has multiple bioactive compounds and thus multiple mechanisms of action to support a robust line of dermatologic therapies that have potential safety, efficacy, and regulatory marketing authorization benefits. Alphyn is headquartered in Annapolis, Maryland and Cincinnati, Ohio, and has a wholly owned subsidiary in Australia. The company began operations in 2020 and has raised approximately $6.9 million.
logo - link
View original content: enlace
